Join Growin Stock Community!

Hca healthcare inc(HCA.US AI Earnings Summary)

US StockHealthcare
No presentation for HCA

HCA AI Earnings Summary (In-Depth)

Last updated: 2026-10-27 (US time)

2026 Q3

Key Takeaways

Demand grew for a 22nd straight quarter and cost control proved resilient; but the shift of exchange enrollees to uninsured is weighing on profit and the 2027 outlook.

  • Stock Price Reaction: HCA Healthcare (HCA) reported before the U.S. market open on October 27, 2026. Although Q3 earnings were solid, the stock closed at $449.96 on 10/27, down 3.29% from the 10/26 close of $465.26, as exchange enrollees becoming uninsured cost about $400M of pretax profit and management struck a cautious tone on 2027 earnings.
  • Market Expectations: Adjusted EPS was $7.22, about 8.6% above the $6.65 TradingView pre-earnings market expectation; revenue was $19.849B, about 2.7% above the $19.33B expectation. Results benefited from strong demand, with same-facility adjusted admissions up 3% and emergency room visits up 5.1%, and from a $50M net benefit from Medicaid supplemental payments.
  • Versus Last Quarter's Guidance: All met. Management reiterated 2026 full-year guidance and, based on strong results in the first three quarters, expects full-year results in the upper half of the ranges (revenue of $77.0B to $79.5B, adjusted EPS of $28.70 to $30.50).
  • In One Sentence: Despite the structural headwind of exchange enrollees becoming uninsured, HCA's 22 straight quarters of demand growth and tight cost control put 2026 full-year results in the upper half of guidance; but the market worried about flat 2027 earnings, and the stock closed down 3.29% on earnings day.

Highlights This Quarter

A 22nd straight quarter of volume growth; core momentum kept strengthening despite headwinds, and management said results were slightly above its expectations.

  1. 22nd straight quarter of volume growth; same-facility adjusted admissions up 3%: Same-facility adjusted admissions rose 3% YoY, above the 2.3% year to date; emergency room visits rose 5.1%, Medicare adjusted admissions 3.2%, Medicaid 2.7%, and commercial (excluding exchanges) 2.7%. Newborn, cardiac, trauma and emergency medical services (EMS) all grew strongly, showing the resilience of a diversified service mix.

  2. Full-year Medicaid supplemental payment expectation raised sharply: About $50M of incremental net benefit was recognized this quarter, lifting the full-year expectation from last quarter's guided $300M to $500M to $600M to $800M, about 75% above the guidance midpoint. The increase mainly came from a newly approved Virginia program and one-time catch-up payments from other states.

  3. Strong core cost control; expense ratio down 40 basis points sequentially: Same-facility cost per equivalent admission (excluding Medicaid supplemental payments) was nearly flat YoY and down 40 basis points from last quarter. CFO Mike Marks noted that expenses usually rise from Q2 to Q3 because of pay adjustments, so this counter-seasonal improvement reflects the strength of resiliency program execution. The salaries, wages and benefits (SWB) margin improved 40 basis points YoY.

  4. Faster revenue-per-unit growth for insured patients (excluding exchanges): Net revenue per equivalent admission growth for insured business was higher than in the first half, driven by 2.7% commercial (excluding exchange) volume growth, solid rate growth across payer classes, and continued improvement in the Parallon collections platform's handling of denials and underpayments.

  5. Quarterly operating cash flow of $4.5B; active capital allocation: Operating cash flow was about $4.5B and capital expenditures about $1.36B; the company repurchased about $3B of stock and paid $165M of dividends. Leverage (debt to adjusted EBITDA) stayed in the lower half of the target range, and the balance sheet remains solid.

  6. 2026 full-year expectations moved to the upper half of the guidance ranges: Management reiterated 2026 guidance (revenue of $77.0B to $79.5B, adjusted EBITDA of $15.4B to $16.1B, adjusted diluted EPS of $28.70 to $30.50) and said it expects to land in the upper half of each range, indicating continued core momentum in Q4.

  7. Record inpatient occupancy; network expansion continues: Company-wide inpatient occupancy reached about 75%, a record. Management is creating extra capacity through patient-flow optimization while continuing to expand its outpatient network, now nearly 3,000 sites including urgent care centers, ambulatory surgery centers and other outpatient facilities.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer